PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27154770-0	2017	Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.	Isothiocyanates	30-45	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102	
27154770-3	2017	The aim of this study was to verify whether combinations of lapatinib with one of isothiocyanates (sulforaphane, erucin or sulforaphene), targeting different levels of HER2 signaling pathway, exert stronger cytotoxic effect than therapy targeting the receptor only, using heterogeneous populations consisting of lapatinib-sensitive and lapatinib-resistant breast cancer cells.	Isothiocyanates	82-97	erb-b2 receptor tyrosine kinase 2	Homo sapiens	168-172	
26134366-0	2015	Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.	Isothiocyanates	85-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21